Lymphoma

A third dose of the mRNA-1273 vaccine for COVID-19 significantly improved SARS-CoV-2 antibody concentrations among patients with hematologic malignancies who previously received two doses, results of a prospective study showed.

Perhaps no one has been better prepared to become a leader in the field of cancer cellular immunotherapy than Marcela V. Maus, MD, PhD.

Patients with early-stage classic Hodgkin lymphoma and other neoplasms exhibited higher risk for cardiovascular disease-associated mortality compared with cancer-associated mortality later in life, according to study results.

Age-adjusted incidence of anaplastic large-cell lymphoma of the breast rapidly increased in the U.S. between 2000 and 2018, according to a research letter published in JAMA Oncology.

Less than half of patients with hematologic malignances exhibited seroconversion after receiving their initial COVID-19 vaccine, research published in Cancer showed.

Nearly 40% of patients who received chimeric antigen receptor T-cell therapy required hospitalization for disease- or treatment-related reasons in the year after infusion, results of a research letter in JAMA Oncology showed.

Patients with hematologic malignancies who resided in rural areas had a lower likelihood of death in a hospice facility but higher likelihood of dying in a nursing facility than their urban counterparts, according to study results.

The FDA approved lisocabtagene maraleucel for treatment of adults with relapsed or refractory large B-cell lymphoma after one prior therapy.

CHICAGO — Second-line therapy with lisocabtagene maraleucel induced initial complete remission among more than half of patients with relapsed or refractory transplant-ineligible large B-cell lymphoma, results from a phase 2 trial showed.

The most common type of cancer in humans is carcinoma.